"Based on the Stanford HIVdb algorithm, drug susceptibility was possibly significantly reduced in 36 patients (10.9%). Among the 15 cases (4.5%) with mutations conferring significant resistance to NRTIs, 10 (3.0%) had intermediate or high level resistance to AZT, D4T, only 3 (0.9%) and 4 (1.2%) patients were predicted to be obviously resistant to TDF and ABC. 5 patients (1.5%) were predicted to have high-level resistance to 3TC and FTC. When NNRTI mutations were present in 22 (6.7%) patients, almost all the patients were predicted to have intermediate to high-level resistance to EFV (n=21, 6.4%) and NVP (n=22, 6.7%), while quite a few patients were resistant to RPV and ETR (n=6, 1.8% and n=3, 0.9% respectively). Cases with PI resistance (n=9, 2.7%) tended to have intermediate or high-level resistance to NFV, seen in n=7, (2.1%) and SQV/r as seen in n=4 (1.2%) patients, who also remained susceptible or had only a potential low-level resistance to DRV/r. Only one (0.3%) patient from this cohort was predicted to have intermediate-level resistance to LPV/r and ATV/r, two patients (0.6%) were predicted to have intermediate-level resistance to FPV/r d TPV/r.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Last date updated on January, 2021